Guggenheim analyst Yatin Suneja downgraded Horizon Therapeutics (HZNP) to Neutral from Buy with a price target of $116.50, up from $98, after the company agreed to be acquired by Amgen (AMGN) for $116.50 per share. The analyst likes the deal for Horizon and downgraded the shares to reflect the proposed deal price.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HZNP:
- John Paulson Hits the Jackpot With Horizon Buyout — Here Are His 2 Top Stocks Right Now
- Amgen price target raised to $299 from $297 at Piper Sandler
- Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargpo
- Horizon Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Horizon Therapeutics downgraded to Hold from Buy at Stifel